期刊文献+

精神分裂症和强迫症记忆监测的比较 被引量:6

Comparative study on memory monitoring between schizophrenia and obsessive-compulsive disorder
原文传递
导出
摘要 目的探讨精神分裂症和强迫症记忆监测的特点。方法对符合DSM.5相应诊断标准的44例精神分裂症患者和42例强迫症患者以及51例正常健康对照进行情景记忆知晓感(FOK)的测验。结果精神分裂症患者线索回忆和再认正确率[0.30(0.15,0.50),0.75(0.56,0.90)]均低于正常对照[0.70(0.50,0.85),0.95(0.85,1.00)]和强迫症患者[0.65(0.39,0.76),0.95(0.84,1.00)],差异具有统计学意义(均P〈0.01)。强迫症患者线索回忆的正确率低于正常对照,差异有统计学意义(P〈0.05)。在高估方面,三组[0.2l(0.00,0.32),0.15(0.00,0.33),0.09(0.00,0.25)]均差异无统计学意义(P〉0.05)。在低估上,精神分裂症患者[0.12(0.00,0.36)]高于强迫症患者[0.00(0.00,0.20)]和正常对照[0.00(0.00,0.22)],差异有统计学意义(分别为P〈0.05,P〈0.01),强迫症患者和正常对照差异无统计学意义(P〉0.05)。精神分裂症患者的Hamann系数[0.19(-0.11,0.43)]低于强迫症患者[0.41(0.13,0.78)]和正常对照[0,56(0.14,1.00)],差异有统计学意义(P〈0.01),强迫症患者和正常对照差异无统计学意义(P〉0.05)。精神分裂症患者(r:0.39,P〈0.01)和正常对照(r=0.52,P〈0.001)的回忆正确率和Hamann系数成正相关。结论精神分裂症患者和强迫症患者的情景记忆均受损,但精神分裂症患者的记忆监测能力受损,强迫症患者完整。 Objective To compare the features of memory monitoring between schizophrenia and obsessive-compulsive disorder in patients. Methods 44 schizophrenia patients and 42 obsessive-compulsive disorder patients who met the DSM-V diagnosis and 51 healthy controls were assessed with feeling-of-knowing (FOK) for episode memory test. Results Schizophrenia patients had significantly poorer cued recall and recognition performance ( 0.30(0.15,0.50) , 0.75 (0.56,0.90) ) compared with healthy controls ( 0.70 ( 0.50, 0.85 ) , 0.95 ( 0.85,1.00) ) and obsessive-compulsive disorder patients ( 0.65 (0.39,0.76) , 0.95 ( 0.84,1.00) ) (all P〈0.001 ).There was significant difference between obsessive-compulsive disorder patients and healthy controls in cued recall performance(P〈0.05).There was no difference among the three groups in overestimate index ( 0.21 (0.00,0.32) , 0. 15 ( 0.00,0.33 ) , 0.09 ( 0. 00,0.25 ) , all P〉 0.05 ). In underestimate index, schizophrenia patients' values ( 0.12 ( 0.00,0.36 ) ) were significantly higher than that of healthy controls ( 0.00 (0.00,0.22)) and obsessive-compulsive disorder patients(0.00(0.00,0.20) ) ( P〈0.05, P〈0.01 ) ,but there was no difference between obsessive-compulsive disorder patients and healthy controls(P〉0.05 ).Schizophre- nia patients' Hamann index ( 0.19 ( -0.11,0.43 ) ) was significantly lower than that of healthy controls ( 0.56 ( 0.14,1.00) ) and obsessive-compulsive disorder patients( 0.41 ( 0.13,0.78 ) ) (P〈0.01) , but there was no difference between obsessive-compulsive disorder patients and healthy controls(P〉0.05).Cued recall performance was positively correlated with Hamann index in patients with schizophrenia ( r= 0.39, P〈 0.01 )and healthy controls( r= 0.52, P〈 0.001 ). Conclusion Patients with schizophrenia and obsessive-compulsive disorder both have episode memory impairments, memory monitoring impairment is observed in schizophrenia patients, but not in obsessive-compulsive disorder patients.
出处 《中华行为医学与脑科学杂志》 CAS CSCD 北大核心 2017年第2期118-122,共5页 Chinese Journal of Behavioral Medicine and Brain Science
基金 国家自然科学基金项目(31571149) 安徽医科大学博士科研资助项目(XJ201533)
关键词 精神分裂症 强迫症 情景记忆 记忆监测 知晓感 Schizophrenia Obsessive-compulsive disorder Episodic memory Memory monitoring Feeling of knowing
  • 相关文献

参考文献6

二级参考文献161

  • 1安宝富,王长虹,李晏.利培酮对精神分裂症认知功能和血清细胞因子水平的影响[J].中国神经精神疾病杂志,2006,32(3):249-252. 被引量:10
  • 2Weickert TW, Goldberg TE, Marenco S,et al. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia : critical examination of confounds [J]. Neumpsychophamiacology, 2003,28(12) :2217 -2218.
  • 3Higuchi Y, Sumiyoshi T, Kawasaki Y, et al. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300 [ J ]. Schizophr Res, 2008,101 ( 1 - 3 ) :320 - 330.
  • 4Brunner E, Gargoloff P, Caro O, et al. The intercontinental schizophrenia outpatient health outcomes study ( IC-SOHO ) : initial 6 month findings of the sample in Latin America [ J ]. Actas Esp Psiquiatr,2006,34( 1 ) :16 -27.
  • 5Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia[ J]. CNS Drugs, 2006,20(5 ) :389 -409.
  • 6Dossenbach M, Arango-Davila C, Silva Ibarra H, et al. Antipsychotic Drugs And Schizophrenia[ J]. N Engl J Med,2006,354(3) :31 -32.
  • 7Brunnauer A, Geiger E, Laux G. Neuroleptics and cognition[ J]. Psychiatr Prax, 2003,30 (Suppl 2) :106 - 109.
  • 8Tandon R, Milner K, Jibson MD. Antipsychotics from theory topractice: inte~ating clinical and basicdata [ J]. J Clin Psychiatry, 1999,60( suppl8 ) :21 - 28.
  • 9Woodward ND, Purdon SE, Mehzer HY,et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia [ J ]. Int J Neuropsychopharmacol,2005,8 ( 3 ) :457 - 472.
  • 10Stip E, Chouinard S, Boulay LJ. On the trail of a cognitive enhancer for the treatment of schizophrenia [ J ]. Prog Neuropsychopharmacol Biol Psychiatry, 2005,29 (2) :219 - 232.

共引文献85

同被引文献46

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部